REG - Oxford Biomedica PLC - Expanded Agreement with BMS’s Juno in CAR-T

Oxford BioMedicaAnnouncement

21/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220721:nRSU2682Ta&default-theme=true

RNS Number : 2682T  Oxford Biomedica PLC  21 July 2022

 

 

The information contained within this announcement is deemed by the Group to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 (as it forms part of domestic law by virtue of the European
Union (Withdrawal) Act 2018). Upon the publication of this announcement via
the Regulatory Information Service, this inside information is now considered
to be in the public domain.

 

 

Oxford Biomedica expands Agreement with Juno Therapeutics, a Bristol Myers
Squibb company; adding two new viral vector programmes for Bristol Myers
Squibb CAR-T therapies

Oxford, UK - 21 July 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a leading gene and cell therapy group, today announces that
it has amended and expanded the License and Clinical Supply Agreement ("LSA")
with Juno Therapeutics, Inc. ("Juno"), a wholly owned subsidiary of Bristol
Myers Squibb Company. The amendment relates to the initiation of two new viral
vector programmes for Bristol Myers Squibb CAR-T therapies.

The LSA, announced in March 2020
(https://otp.investis.com/clients/uk/oxford_biomed1/rns/regulatory-story.aspx?cid=544&newsid=1379937)
, granted Juno a non-exclusive license to Oxford Biomedica's LentiVector(®)
platform to be used for the manufacture of viral vectors for CAR-T and TCR-T
programs in oncology and other indications.

Under the terms of the amendment, Oxford Biomedica will receive an undisclosed
target nomination fee, as well as potential payments upon the achievement of
certain milestones.

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica
commented: "Bristol Myers Squibb is a strategically important partner to
Oxford Biomedica and we are pleased to announce this expansion of our License
& Clinical Supply Agreement. BMS is a proven commercial and clinical
leader in the CAR-T field and we are pleased to announce the initiation of the
two new programmes, taking the number of programmes we are working on with BMS
to six. We look forward to announcing further updates on this important
partnership in due course."

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal / Matthew Cole

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFIFSEDFILFIF